PPT-All About Costs

A PostAward Primer Division of Grants Compliance and Oversight Office of Policy for Extramural Research Administration OER National Institutes of Health DHHS NIH Regional Seminar Baltimore MD June 2014. Some people with limited resources and income also may be able to get Extra Help to pay for the costsmonthly premiums annual deductibles and prescription copaymentsrelated to a Medicare prescription drug plan The Extra Help is estimated to be worth Raising . a Child. Your half million . dollar child…. Children are priceless, but . raising them is probably the . most expensive thing you'll . ever do. Here are some . breakdowns on where the . expenses may be. . AccuCirc. and . Mogen. . Clamp. Karin . HAtzOld. , MD, MPH . Population Services International. Collin Mangenah, . CeSSHAR. Zimbabwe . Harsha Thirumurthy, UNC . 8. th. International AIDS Economics Network. The 4C Project – A Collaboration to Clarify the Costs of Curation. APARSEN Webinar: 13 June 2013. Neil Grindley – 4C Project Coordinator. Jisc Programme Manager: Digital Preservation and Curation. Thanks for inviting me …. Managing, archiving, curating, preserving and sustaining digital [research] outputs …. neil.grindley@jisc.ac.uk. Head of Resource Discovery & 4C Project Coordinator. Istanbul 7/4/2014. Agenda. Today’s trends. Today’s trends. Results are under pressure. Reduce head count. Decrease overhead costs. Challenging market. Commoditisation. Changing consumer demands. Legal framework shifting. How much does it cost?. History . At Great Brickhill Cricket Club a number of years ago, due to the arduous task of collecting playing subscriptions it was decided to adopt a ‘Pay as you Play’ policy. UH . Manoa. MEC . November 14, 2013. Office of Research Services. Purpose of F&A Rate. 2. = Research . F. & . A. Rate. +. F & A Research Rate Formula. 3. Last 5 Negotiated F & A Rates. REC Infrastructure Retreat. April 7, 2015. Nancy L. Wilkinson, Office of the Dean for Research (IFAS). Understanding Indirect Costs. – . Today’s Agenda. . Definition. Key Concepts – Facilities & Administrative. Award and Assessment of Costs. Hong . Kong 2017 . Mary Thomson. . Chartered Arbitrator, Barrister, Mediator & Adjudicator. Vice Chair, CIArb EAB . . 1. Award . and Assessment of Costs. Introduction. eventsof. . nivolumab. and . docetaxel. in the . CheckMate. 017 and . CheckMate. 057 phase III NSCLC trials. . Kartik. . Venkatachalam. Intervista a Cesare . Gridelli. Background: Nivo, a PD-1 antibody, received FDA approval based on superior overall survival in metastatic squamous (SQ) and non-squamous (NSQ) NSCLC patients who have progressed on or after platinum-based doublet chemotherapy. The purpose of this study was to assess the frequency and associated costs of grade 2–4 AEs in the CheckMate 017 (SQ) and CheckMate 057 (NSQ) phase III pivotal trials of nivo vs doc in stage IIIB/IV NSCLC. Methods: Patient-level data from these two trials were utilized to estimate the frequency of TRAEs requiring management in the nivo and doc arms, including serious and non-serious TRAEs. Minimum follow-up for AE reporting at database lock was 12 months. Grade 3–4 AE costs by event were identified from Healthcare Cost and Utilization Project (HCUP) data in 2010, which were adjusted to reflect 2012-equivalent US costs. Healthcare utilization associated with grade 2 AEs was based on clinical opinion and costs were based on HCUP or other sources as appropriate. Results: In both trials, more TRAEs were observed with doc than with nivo (Table), and the cost of managing TRAEs was 15.8 and 10.7 times higher in the doc arm vs the nivo arm for the CheckMate 017 and CheckMate 057 trials, respectively. Patients in the doc arm incurred an additional $6,585 and $5,422 per patient in managing AEs compared with patients in the nivo arm in the above two trials, respectively. The total estimated costs of managing TRAEs during these trials are presented in the Table. Conclusions: Large estimated differences in costs were observed in managing TRAEs, favoring nivo in the CheckMate 017 and CheckMate 057 pivotal trials. The reduction in costs for managing AEs with the use of nivo should be considered when assessing the value of nivo in this patient population.. AP Microeconomics. UHS. Barnett. Total Revenue, Total Cost, Profit. We assume that . the firm’s goal is to maximize profit. .. Profit. = . Total revenue. – . Total cost. the amount a firm receives from the sale of its output. AP Economics. Mr. Bordelon. Profit. Profit.. . . T. otal revenue minus total cost. π means “profit.”. π = TR – TC. Total revenue.. Price of output times the quantity sold.. TR = PQ. Total cost.. & maintenance costs, life Cycle costs and . Levelized. cost of electricity. Lec. 5. SEPPA. MSESSD. 03 Aug 2016. Capitalized Equivalent Method. 8/3/2016. 2. Capitalized Equivalent Method. . Another method of PV criterion is useful when the...